Home Tags DLBCL

Tag: DLBCL

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large...

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA minor groove interstrand cross-linking...
Featured Image: Cancer cell Courtesy: © 2018. Fotolia. Used with permission.

FDA Grants Accelerated Approval of Polatuzumab Vedotin in Select Patients

The U.S. Food and Drug Administration (FDA) today confirmed that it has granted accelerated approval of polatuzumab vedotin-piiq (Polivy™; Genentech; previously known as DCDS4501A...
Featured Image: Close-up cityscape of Lugano city waterfront along Lugano Lake. Facades of historic houses in front of alp mountains. Courtesy: © 2017. Fotolia. Used with permission.

Updates from the 14th International Conference on Malignant Lymphoma (ICML)

Since the inaugurational meeting in 1981, the International Conference on Malignant Lymphoma (ICML), traditionally takes place in Lugano, Switzerland, has become one of the...

Novel ADC Technology Demonstrated Strong Preclinical Antitumor Activity in B-cell Malignancies...

Lymphomas, a group of cancers that originate in the lymphatic system, include both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Non-Hodgkin lymphoma, which is...

Denintuzumab Mafodotin: Testing Novel Regimens for Frontline and Relapsed DLBCL

Highlighted clinical data with denintuzumab mafodotin (SGN-CD19A; 19A; Seattle Genetics) in B-cell malignancies, including diffuse large B-cell lymphoma, also known as DLBCL, and B-lineage...

Phase II Trial of Denintuzumab Mafodotin Combination Therapy in Relapsed or...

A randomized phase II clinical trial of denintuzumab mafodotin, also known as SGN-CD19A (SGN-19A), in combination with the second-line salvage regimen of rituximab (Rituxan®;...

Phase II Clinical Trial of Brentuximab Vedotin Combination Therapy in...

Based on encouraging data in patients with CD30-expressing relapsed or refractory diffuse large B-cell lymphoma or DLBCL, the most common type of aggressive non-Hodgkin Lymphoma...

First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...

Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...

Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...

Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...

Polatuzumab Vedotin and Pinatuzumab Vedotin + Rituximab Generally Well-tolerated With Similar...

Updated data on the investigational antibody-drugs conjugates polatuzumab vedotin (anti-CD79b; DCDS4501A) and pinatuzumab vedotin (anti-CD22; DCDT2980S) were presented during the 56th Annual Meeting and...

FEATURED RESOURCES